At-home brain stimulation OK'd
- The FDA approved the first at-home brain-stimulation device for adults with major depressive disorder. - The approval permits regulated, self-administered neuromodulation therapy outside clinical settings. - Regulators' move accelerates remote psychiatric treatment delivery and raises questions about access, patient selection, and device safety. (psychiatrictimes.com)
A depression headset that sends a weak electrical current through the scalp can now be prescribed for home use in the United States for some adults with major depressive disorder. (fda.gov) The Food and Drug Administration approved Flow Neuroscience’s FL-100 on December 8, 2025, for adults 18 and older with moderate to severe major depressive disorder in a current episode. The label allows use either alone or alongside other treatment, but not for patients the agency considers treatment-refractory to medication. (fda.gov) The device uses transcranial direct current stimulation, or tDCS, which works like a low-power circuit: electrodes on the scalp deliver 2.0 milliamps of current to brain areas involved in mood. In Flow’s system, patients wear a Bluetooth-connected headset and use saline-soaked pads to conduct the signal. (fda.gov) The approval rests on a fully remote phase 2 trial published in *Nature Medicine* on October 21, 2024. Researchers randomized 174 adults to active or sham treatment, with 30-minute sessions five times a week for three weeks and then three times a week for seven weeks. (nature.com) By week 10, patients using active stimulation improved by 9.41 points on the 17-item Hamilton Depression Rating Scale, compared with 7.14 points in the sham group. The study found no difference in discontinuation rates between the two groups. (nature.com) The Food and Drug Administration’s own review was more cautious than the headlines. The agency said there was “moderate” uncertainty about the size of the benefit because of unblinding, no prespecified threshold for clinically meaningful change, and mixed findings in earlier literature. (fda.gov) The label also narrows who should use it. The device is contraindicated for people with open or damaged skin where the electrodes sit and for people with metallic skull reconstruction at the electrode site. (fda.gov) Reported side effects were mostly local and temporary, including stinging, burning, itching, skin dryness, skin irritation or redness, and transient headache. Company materials and follow-up coverage said skin burns have occurred when pads were reused or allowed to dry out. (empr.com, usnews.com) The decision opens a new lane between antidepressants and clinic-based procedures such as transcranial magnetic stimulation, which usually require repeated office visits. In the United States, major depression affected an estimated 21 million adults in the most recent National Survey on Drug Use and Health data cited by the National Institute of Mental Health. (fda.gov, nimh.nih.gov) Flow told trade publications the device is expected to launch in the United States in 2026, with a price range of about $500 to $800. The next test is not whether the headset can be shipped, but which patients can get prescribed, trained, and monitored safely outside a clinic. (psychiatrictimes.com)
